Allogene Therapeutics, Inc.

ALLO

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001737287

SEC filings (opens in a new tab)

In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Allogene Therapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024 All holders in Q2 2024

13F holders of ALLO: Q2 2024 compared with Q3 2024
Measure	Q2 2024	Of which not filed for Q3 2024	Q3 2024	Change
Holders	175	2	156	−17
Shares	165.3M	16.9M	164.4M	+16.0M (+10.8%)
Value	$385.1M	$39.3M	$460.4M	+$114.6M (+33.1%)

2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (11)

Institutions that held Allogene Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to ALLO in Q3 2024
Institution	Shares	Value	% of portfolio
BlackRock, Inc.	17,772,745	$49.8M	0.00%
Zacks Investment Management	516,601	$1.45M	0.01%
Engineers Gate Manager LP	47,773	$133.8K	0.00%
Intech Investment Management LLC	41,331	$115.7K	0.00%
Simplex Trading, LLC	27,130	$75.0K	0.00%
MML Investors Services, LLC	20,000	$56.0K	0.00%
Private Advisor Group, LLC	12,087	$33.8K	0.00%
nVerses Capital, LLC	3,100	$8.68K	0.00%
Quadrant Capital Group LLC	760	$2.13K	0.00%
Sterling Capital Management LLC	449	$1.26K	0.00%
Capital Performance Advisors LLP	41	$115	0.00%

Sold out (28)

Institutions that held Allogene Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of ALLO in Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
Boxer Capital, LLC	3,850,000	$8.97M
Jacobs Levy Equity Management, Inc	878,955	$2.05M
Gsa Capital Partners LLP	835,342	$1.95M
Jump Financial, LLC	169,348	$394.6K
Pennant Investors, LP	128,400	$299.2K
Los Angeles Capital Management LLC	125,030	$291.3K
EntryPoint Capital, LLC	92,752	$216.1K
PDT Partners, LLC	85,610	$199.5K
Russell Investments Group, Ltd.	80,197	$186.9K
Tudor Investment Corp Et Al	71,340	$166.2K
Public Employees Retirement System of Ohio	57,300	$133.5K
Balyasny Asset Management LLC	53,622	$124.9K
Bayesian Capital Management, LP	35,402	$82.5K
Schonfeld Strategic Advisors LLC	17,192	$40.1K
Principal Financial Group Inc	16,836	$39.2K
Clarity Wealth Advisors, LLC	15,632	$36.4K
Algert Global LLC	14,808	$34.5K
Dynamic Technology Lab Private Ltd	14,085	$33.0K
Inceptionr LLC	11,062	$25.8K
Atom Investors LP	10,833	$25.2K
Itau Unibanco Holding S.A.	6,355	$14.8K
Pacer Advisors, Inc.	2,372	$5.53K
Nordwand Advisors, LLC	1,000	$2.33K
Abich Financial Wealth Management LLC	283	$659
Bell Investment Advisors, Inc	161	$376
Lindbrook Capital, LLC	117	$273
Dunhill Financial, LLC	70	$163
Toronto Dominion Bank	27	$63

Not filed for Q3 2024 yet (2)

Institutions that held Allogene Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ALLO in Q2 2024 that haven't filed for Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
BlackRock Inc.	16,445,682	$38.3M
Susquehanna Fundamental Investments, LLC	418,699	$975.6K